ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 178 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $2,091,000 | +513.2% | 25,250 | +389.9% | 0.19% | +551.7% |
| Q1 2021 | $341,000 | -67.1% | 5,154 | -61.9% | 0.03% | -65.5% |
| Q4 2020 | $1,037,000 | -43.8% | 13,516 | -68.5% | 0.08% | -47.8% |
| Q3 2020 | $1,845,000 | +22.4% | 42,864 | +22.8% | 0.16% | +3.9% |
| Q2 2020 | $1,507,000 | -65.2% | 34,893 | -76.8% | 0.16% | -67.2% |
| Q1 2020 | $4,327,000 | +23.3% | 150,401 | +171.9% | 0.47% | +345.3% |
| Q4 2019 | $3,508,000 | +15.6% | 55,315 | -51.7% | 0.11% | -10.2% |
| Q2 2019 | $3,034,000 | +68.7% | 114,504 | +16.8% | 0.12% | +13.5% |
| Q1 2019 | $1,798,000 | +785.7% | 98,005 | +77.2% | 0.10% | +3366.7% |
| Q4 2017 | $203,000 | +866.7% | 55,300 | +385.1% | 0.00% | – |
| Q1 2017 | $21,000 | -80.2% | 11,400 | -83.5% | 0.00% | -100.0% |
| Q4 2016 | $106,000 | -10.2% | 68,900 | +328.0% | 0.00% | -25.0% |
| Q3 2016 | $118,000 | -10.6% | 16,100 | -35.3% | 0.00% | -33.3% |
| Q2 2016 | $132,000 | – | 24,900 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,303 | $54,386,000 | 28.54% |
| JOHNSON & JOHNSON | 3,260,869 | $216,196,000 | 24.61% |
| ACT CAPITAL MANAGEMENT, LLC | 210,500 | $13,956,000 | 10.09% |
| Aquilo Capital Management, LLC | 700,426 | $46,438,000 | 5.27% |
| WEALTH EFFECTS LLC | 145,960 | $9,677,000 | 4.02% |
| Evolutionary Tree Capital Management, LLC | 115,580 | $7,663,000 | 3.68% |
| ACUTA CAPITAL PARTNERS, LLC | 105,500 | $6,995,000 | 2.94% |
| Privium Fund Management B.V. | 204,393 | $13,766,000 | 2.73% |
| L1 Capital Pty Ltd | 292,735 | $19,408,000 | 2.24% |
| Avidity Partners Management LP | 875,000 | $58,013,000 | 1.23% |